NeuroPace, Inc. (NPCE) News

NeuroPace, Inc. (NPCE): $4.90

-0.20 (-3.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NPCE News Items

NPCE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NPCE News From Around the Web

Below are the latest news stories about NeuroPace Inc that investors may wish to consider to help them evaluate NPCE as an investment opportunity.

NeuroPace to Report Fourth Quarter and Full Year 2021 Financial Results and Present at the 11th Annual SVB Leerink Global Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the fourth quarter and full year of 2021 after market close on Thursday, March 10, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time. Investors interested in lis

Yahoo | January 27, 2022

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue

MOUNTAIN VIEW, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021. Based on available financial information, preliminary unaudited fourth quarter 2021 revenue is expected to be approximately $11.0 million, compared to $10.8 million in the fourth quarter

Yahoo | January 11, 2022

NeuroPace to Present at 40th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Administration, and Irina Ridley, General Counsel and Corporate Secretary will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th, 2022, at 8:15 am Pacific Time / 11:15am East

Yahoo | December 16, 2021

NeuroPace, Inc. (NPCE) Q3 2021 Earnings Call Transcript

Image source: The Motley Fool. NeuroPace, Inc. (NASDAQ: NPCE)Q3 2021 Earnings CallNov 10, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon and welcome to NeuroPace's third quarter earnings conference call.

Yahoo | November 11, 2021

NeuroPace Reports Third Quarter 2021 Financial Results

MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Total revenue of $10.3 million for the third quarter of 2021, representing a 19% decrease over the prior year period in 2020Initial implant revenue of $7.8 million for the third quarter of 2021, representing

Yahoo | November 10, 2021

NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation to treat primary generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc., a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced that it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to study the company’s RNS® System in pa

Yahoo | November 10, 2021

NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021

MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of 2021 after market close on Wednesday, November 10, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time. Investors interested in listening to t

Yahoo | October 20, 2021

NeuroPace Announces Addition of Lisa Andrade to the Board

MOUNTAIN VIEW, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc., (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors. Simultaneously, the company also announced the resignation of current board member, Evan Norton. Both changes are effective November 1, 2021. Lisa Andrade joins NeuroPace with over 25 years of experience in both large and early-stage medtec

Yahoo | October 19, 2021

Calculating The Fair Value Of NeuroPace, Inc. (NASDAQ:NPCE)

Today we will run through one way of estimating the intrinsic value of NeuroPace, Inc. ( NASDAQ:NPCE ) by taking the...

Yahoo | September 20, 2021

NeuroPace to Participate in Upcoming Conferences

MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported that the company will be participating in three upcoming conferences. 2021 Wells Fargo Virtual Healthcare ConferenceFireside Chat on Friday, September 10, 2021, at 9:20 a.m. Eastern Time / 6:20 a.m. Pacific Time. 19th Annual Morgan Stanley Global Healthcare ConferenceFireside Chat on

Yahoo | August 23, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4545 seconds.